Patents Examined by Barbara P. Badio
  • Polymorphs of CDDO ethyl ester and uses thereof
    Patent number: 9656951
    Abstract: The present invention relates to polymorphic forms of the compound of Formula I (i.e., ethyl 2-cyano-3,12-dioxoIeana-1,9(11)-dien-28-oate (CDDO ethyl ester)) and methods of using them for treating a variety of disease states such as cancer and condisitons associated with inflammation.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: May 23, 2017
    Assignee: Applied Pharmaceutical Science, Inc.
    Inventors: Xiaohong Zhang, Lu Song, Wendong Sun, Kaiyang Liu, Chunlei Han
  • Amine compound and use thereof for medical purposes
    Patent number: 9657043
    Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: May 23, 2017
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Maiko Hamada, Kaoru Tashiro, Hiroshi Sakashita, Masatoshi Kiuchi, Shuzo Takeda, Kunitomo Adachi
  • TGR5 modulators and methods of use thereof
    Patent number: 9650409
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 16, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Crystalline polymorphic form of ulipristal acetate
    Patent number: 9643993
    Abstract: A novel crystalline polymorphic form of ulipristal acetate useful as an agent for preventing and/or treating uterine leiomyoma and as a contraceptive, and a process for producing the crystalline polymorphic form are provided. The novel crystalline polymorphic form of ulipristal acetate is obtained by dissolving an isopropanol-solvated crystal of ulipristal acetate in a mixed solvent containing ethanol and water, and crystallizing an ulipristal acetate from the solution without addition of a seed crystal to the solution.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 9, 2017
    Assignee: Aska Pharmaceutical Co., Ltd.
    Inventors: Shigeki Iwashita, Hiroyuki Hayashi, Koichi Miyazaki
  • Crystalline polymorphic form of ulipristal acetate
    Patent number: 9643994
    Abstract: A novel crystalline polymorphic form of ulipristal acetate useful as an agent for preventing and/or treating uterine leiomyoma and as a contraceptive, and a process for producing the crystalline polymorphic form are provided. The novel crystalline polymorphic form of ulipristal acetate is obtained by crystallization or transition in association with a specified solvent. The solvent comprises at least one member selected from the group consisting of water, an aliphatic hydrocarbon, an aromatic hydrocarbon, a halogenated hydrocarbon, a linear alcohol, an alkyl ether, an acetate ester, an alkyl ketone, an N-alkylacylamide, and an alkanenitrile.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 9, 2017
    Assignee: Aska Pharmaceutical Co., Ltd.
    Inventors: Shigeki Iwashita, Hiroyuki Hayashi, Koichi Miyazaki
  • Betulinic acid proline derivatives as HIV inhibitors
    Patent number: 9637516
    Abstract: The invention relates to novel betulinic acid derivatives and related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: May 2, 2017
    Assignee: HETERO RESEARCH FOUNDATION
    Inventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Lanka Vl Subrahmanyam, Gazula Levi David Krupadanam, Mukkera Venkati, Neela Sudhakar, Kallem Srinivas Reddy
  • Synthetic bile acid compositions and methods
    Patent number: 9636349
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: May 2, 2017
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Farnesoid X receptor modulators
    Patent number: 9611289
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 4, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Substituted quinoline compounds and methods of use
    Patent number: 9598400
    Abstract: The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: March 21, 2017
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventor: Ning Xi
  • Geranyl flavonoid derivative with improved water solubility, a method for preparing the same, and a method for treating cancer using the same
    Patent number: 9580399
    Abstract: The present invention relates to a novel geranyl flavonoid derivative with improved water-solubility or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a method for treating cancer using the same. Particularly, the novel geranyl flavonoid derivative of the present invention inhibits the expression of STAT3 target protein by suppressing the phosphorylation of STAT3 (Signal Transducers and Activators of Transcription 3) protein, suggesting that it has cancer cell growth inhibiting effect in various cancer cell lines. Also, the compound of the invention has the effect of reducing the size and weight of a tumor significantly in vivo, so that the geranyl flavonoid derivative or the pharmaceutically acceptable salt thereof can be efficiently used for the treatment of cancer.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: February 28, 2017
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Byoung-Mog Kwon, Dong Cho Han, Yoon-Jeong Jeon, Joongku Lee, Sangho Choi
  • Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
    Patent number: 9579270
    Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: February 28, 2017
    Assignee: Duke University
    Inventors: Mitchell A. deLong, John M. McIver, Robert S. Youngquist
  • Triterpenoids and compositions containing the same
    Patent number: 9539287
    Abstract: The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: January 10, 2017
    Assignee: Trustees of Dartmouth College
    Inventors: Gordon W. Gribble, Liangfeng Fu, Michael B. Sporn, Karen T. Liby
  • TGR5 modulators and methods of use thereof
    Patent number: 9540414
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: January 10, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Substituted tetracycline compounds
    Patent number: 9533943
    Abstract: The present invention pertains, at least in part, to novel substituted etracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: January 3, 2017
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Todd Bowser, Mark Grier
  • Synthetic bile acid compositions and methods
    Patent number: 9522155
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: December 20, 2016
    Assignee: KYTHERA BIOPHARMACEUTICALS, INC.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
    Patent number: 9518080
    Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: December 13, 2016
    Assignees: RESEARCH TRIANGLE INSTITUTE, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Scott P Runyon, Michael Rogawski, Edgar Cook, John Kepler, Hernan Navarro, Rafal Kaminski, Matthew Orr
  • Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
    Patent number: 9512167
    Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: December 6, 2016
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Markus Proels, Erik Fischer, Heidi Waenerlund Poulsen
  • Agonists that enhance binding of integrin-expressing cells to integrin receptors
    Patent number: 9512109
    Abstract: A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of ?4?1, ?5?1, ?4?7, ?v?3 and ?L?2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: December 6, 2016
    Assignee: TEXAS HEART INSTITUTE
    Inventors: Ronald J. Biediger, William C. Gundlach, IV, Robert V. Market, Michael M. Savage, Peter Vanderslice
  • Compound, composition and method for treating and/or ameoliorating kidney disease
    Patent number: 9512168
    Abstract: Disclosed herein are compositions and methods for the treatment or prophylaxis of a subject having or susceptible to a kidney disease. The method includes the step of administering to the subject a compound of formula (I) in a dose of about 1 to 10 mg/Kg to improve the glomerular filtration rate (GFR) of the subject for at least 4 folds as compared to the GFR of the subject before treatment, The method further includes the step of administering to the subject an effective amount of lucidenic acid C (LAC), lucidenic acid N (LAN), lucidenic acid E2 (LAE2), lucidenic acid A (LAA), and lucidenic acid D2 (LAD2).
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: December 6, 2016
    Inventors: Cheng-Po Huang, Teng-Hai Chen, Kuang Dee Chen, Chun-Tao Su
  • Cocrystals of progesterone
    Patent number: 9512166
    Abstract: Disclosed herein are cocrystals of progesterone and a coformer containing a six-membered aromatic ring having at least one substituent possessing a carbonyl functionality. Cocrystals of progesterone and a coformer selected from vanillic acid, benzoic acid, salicylic acid, cinnamic acid, or vanillin are also disclosed herein.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: December 6, 2016
    Assignee: AMRI SSCI, LLC
    Inventors: Ekaterina Albert, Patricia Andres, Melanie Janelle Bevill, Jared Smit, Jennifer Nelson